Synergen Bio Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 09-01-2025
- Paid Up Capital ₹ 5.10 M
as on 09-01-2025
- Company Age 6 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 38.53 Cr
as on 09-01-2025
- Satisfied Charges ₹ 11.25 Cr
as on 09-01-2025
- Revenue 15.31%
(FY 2023)
- Profit -25.58%
(FY 2023)
- Ebitda -3.23%
(FY 2023)
- Net Worth 40.67%
(FY 2023)
- Total Assets 29.88%
(FY 2023)
About Synergen Bio
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 5.10 M.
The company currently has active open charges totaling ₹38.53 Cr. The company has closed loans amounting to ₹11.25 Cr, as per Ministry of Corporate Affairs (MCA) records.
Neel Lahoti and Puneet Verma serve as directors at the Company.
- CIN/LLPIN
U74999PN2018PTC177201
- Company No.
177201
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jun 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Synergen Bio?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neel Lahoti  | Whole-Time Director | 14-Jun-2018 | Current |
| Puneet Verma | Whole-Time Director | 30-Jan-2020 | Current |
Financial Performance of Synergen Bio.
Synergen Bio Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 15.31% increase. The company also saw a substantial fall in profitability, with a 25.58% decrease in profit. The company's net worth Soared by an impressive increase of 40.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Synergen Bio?
In 2023, Synergen Bio had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 26 Mar 2024 | ₹1.00 Cr | Open |
Yes Bank Limited Creation Date: 29 Feb 2024 | ₹1.34 Cr | Open |
Yes Bank Limited Creation Date: 09 Nov 2023 | ₹1.04 Cr | Open |
How Many Employees Work at Synergen Bio?
Synergen Bio has a workforce of 71 employees as of Jan 09, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Synergen Bio, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Synergen Bio's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
